Company attributes
Other attributes
Betalin Therapeutics is developing an Engineered Micro Pancreas (EMP) to improve the quality of life for people with diabetes. The company is headquartered in Ramat Gan, Israel and was founded in 2015 by Shay Hershcovich and Shuki Joshua Hershcovich.
Betalin Therapeutics licensed the EMP technology developed at The Hebrew University of Jerusalem, Israel, in agreement in 2015. The Hebrew University continues to partner with Betalin Therapeutics to support the research and development.
Interview with
Based on in vitro results and preliminary in vivo results, Betalin Therapeutics submitted a pre-pre-IND (Investigational New Drug) application to the Food and Drug Administration (FDA). Following the FDA's positive response, Betalin Therapeutics is preparing the pre-IND meeting on its way towards IND submission.
Betalin Therapeutics was raising funding in 2018 in order to further optimize the therapy in animal models, complete submission of the IND application to the FDA, and proceed to clinical trials. Betalin Therapeutics was awarded a competitive matching grant from the Office of the Chief Scientist.
On January 11, 2017 Betalin Therapeutics completed their seed funding round with €50,000 in funding from the European Union executive agency for SMEs.
